Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Tekmira Pharmaceuticals — Merger or Acquisition (January 2015)
13 slides from Arbutus Biopharma's merger presentation, Jan 12, 2015
Slide 1: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company Transaction Overview January 12, 2015 o Tekmira | QnCore BIoPHaRMA, INC.
Slide 2: Forward Looking Statements
Forward Looking Statements
Slide 3: Proven leadership
Proven leadership ¢ Mark Murray, Chief Executive Officer Patrick Higgins, President and Chief Operating Officer Bruce Cousins, Chief Financial Officer ¢ Michael Sofia, Chief Scientific Officer William Symonds, Chief Development Officer ¢ Mark Kowalski, Chief Medical Officer « Mike Abrams, Chief Disc
Slide 4: Meeting a significant unmet medical need
Meeting a significant unmet medical need ‘ a - ~~ 7 80 M people die every year @ Chronic HBV Infections @ HBV Genotypes (A-H) » Tekmita | oto Soares WHO, CDC.
Slide 5: Transaction Highlights
Transaction Highlights Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders Expected to create the industry’s leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need
Slide 6: Tekmira non-HBV programs
Gy Tekmita Gastrointestinal Neuroendocrine Tumors Adrenocortical Carcinoma Hepatocellular Carcinoma Ebola Virus Infection Ebola Virus Infection Marburg Vitus Infection re Forms of Hypertriglyceridemi a Glycogen Storage Disorder Type IV Alcohol Use Disorder OkCore kmira non-HBV programs TKIV-PLKL: GI
Slide 7: Working towards a curative regimen for HBV
Working towards a curative regimen for HBV Hepatitis B is a bigger market than Hepatitis C Provide a cure by delivering multiple mechanisms of action against the iru — AQ ively suppr iral replication — Stimulate or reactivate the immune system — Eliminate cccDNA Of all mechanisms of action, we belie
Slide 8: TKM-HBV: Targeting Multiple HBV Transcripts
TKM-HBV: Targeting Multiple HBV Transcripts Design an anti-HBV RNAi Trigger “payload” that is: especially HBsAg Uni 1 effecti Trigger sites that target 3 viral transcripts Trigger sites that target all 4 viral kb and 0.7 kb MRNA and pgRNA with transcripts potential for HBx and core Ag
Slide 9: OnCore-Tekmira development pipeline
OnCore-Tekmira development pipeline Immunesystem c:cDRA Formation HBVReplcation stimulation/ Inbiition Inbiition Reactivation mination LUcense from NouroVive = Py e : = Teen pee Eeeeeey Secon ihikor e ‘equation of Eoenasn =n : eee =» e =» conse from ‘ecONA Epigonetc Mediior Blumbers/Orexe Pra | OfCo
Slide 10: Combination Development Strategy
Combination Development Strateg Phase 2 Combo. al Rep Immune System apressi Stimulation Phase 1 Phase 1/2 Single/Multiple Proof of Concept* Ascending Dose Immune System J Immune System Stimulation Stimulation Immune System Stimulation *willinitially combine with Immune System existing NUC therapy St
Slide 11: OnCore-Tekmira Transaction Details
OnCore-Tekmira Transaction Details OnCore will become a wholly-owned subsidiary of Tekmira Merger of equals as determined by the treasury stock method Implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, is
Slide 12: Conclusion
Conclusion Combined company well positioned to capitalize on the global market ea in HBV and create significant long-term value for shareholde Expected to create the industry's leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need 8 unique drug candidat
Slide 13: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company Transaction Overview January 12, 2015 o Tekmira | QnCore BIoPHaRMA, INC.
Tekmira Pharmaceuticals — Merger or Acquisition (January 2015) on 6ix